Biogen and IDEC Pharmaceuticals, two rivals racing to develop drugs for cancer and other diseases, announced plans Monday to merge and create the No. 3 biotechnology company, the latest of a string of ...

Biogen Idec has ended development of its dexpramipexole for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), after the drug candidate failed a pivotal Phase III clinical trial—though the ...

Biogen Idec (NASDAQ: BIIB) and Columbia University Medical Center have formed a $30 million strategic alliance to conduct genetics discovery research on the underlying causes of disease and to ...

Contract drug manufacturer Patheon has named former chief executive of Biogen Idec to be the company’s new CEO. James Mullen’s appointment to lead Patheon (TSX:PTI), based in North Carolina’s Research ...

During the early days of the biotechnology industry, there were several bellwether companies that analysts and other industry observers kept an eye on to get a sense of the biobusiness world’s health ...

Great biotech companies tend to dominate at least one indication. In Biogen's case, that indication is multiple sclerosis. Biogen's Avonex and Tysabri are long-standing blockbuster treatments for ...

The search is on for a new head. Mullen rose through the ranks at Biogen after coming on as director of facilities and engineering in 1989. He became head of Biogen in 2000, and kept that post when ...

Biogen Idec uses cutting-edge science to discover, develop, manufacture and market biological products for the treatment of serious diseases with a focus on neurological disorders. Founded in 1978, ...

Idec Pharmaceuticals Corp. and Biogen Inc. announced yesterday that they would merge in a $6.8 billion deal that will create a powerhouse in the biotechnology industry, with the new company earning ...

The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, saying it unfairly lumped failed drugs with two recently approved treatments ...